Akèy › Maladi fwa steatotik › New York › New York City
Etid klinik pou Maladi fwa steatotik nan New York City, NY
16 etid pou Maladi fwa steatotik ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Ap rekriteFaz 3
- 89bio Clinical Study Site, New York
- 89bio Clinical Study Site, New York
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Ap rekriteFaz 3
- 89bio Clinical Study Site, New York
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Ap rekriteFaz 3
- GSK Investigational Site, New York
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
Ap rekriteFaz 2
- New York Presbyterian/Weill Cornell, New York
- Columbia University Iriving School of Medicine, New York
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Ap rekriteFaz 2
- Columbia University Irving Medical Center, New York
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Ap rekriteFaz 3
- NYU Langone Health, New York
- IMA Clinical Research Manhattan, New York
- New York Gastroenterology Associates, New York
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Ap rekriteFaz 3
- Akero Clinical Study Site, New York
- Akero Clinical Study Site, New York
- Akero Clinical Study Site, New York
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Ap rekriteFaz 3
- GSK Investigational Site, New York
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Ap rekriteFaz 1Volontè an sante akeyi
- Columbia University Irving Medical Center, New York
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
Ap rekriteFaz 2
- GSK Investigational Site, New York
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Ap rekriteFaz 3
- GSK Investigational Site, New York
- GSK Investigational Site, New York
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Ap rekriteFaz 2
- GSK Investigational Site, New York
Effect of Insulin Lowering on Lipogenesis
Ap rekriteFaz 1
- Columbia University Irving Medical Center, New York
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Ap rekrite
- Icahn School of Medicine at Mount Sinai, New York
Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
Ap rekriteVolontè an sante akeyi
- Weill Cornell Medicine, New York
High Fructose Diet, the Gut Microbiome, and Metabolic Health
Ap rekriteVolontè an sante akeyi
- Mount Sinai Morningside, New York
Etid Maladi fwa steatotik nan lòt vil
- San Antonio, TX17 etid
- Miami, FL16 etid
- San Diego, CA14 etid
- Austin, TX13 etid
- Houston, TX13 etid
- Richmond, VA12 etid
- Tucson, AZ10 etid
- Chandler, AZ10 etid
- St. Louis, MO9 etid
- Hialeah, FL9 etid
- Dallas, TX9 etid
- Orlando, FL9 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.